The company gets another odronextamab knockback, while a key fianlimab readout is postponed.

The first data are dribbled out, but cross-trial comparisons look uninspiring.

Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.

Jazz’s Chimerix buy faces its big test.

More data from onvansertib's phase 2 study fail to convince.